Superworth

Amgen EV/EBIT AMGN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Oct 23, 2026
24.6×
10-year median
16.8×
Against its 10-year history
87th
percentile: 0 is its lowest day, 100 its highest
10-year range
10.5× to 32.8×
Peer median
23.4×

Amgen's EV/EBIT is 24.6× as of Oct 23, 2026.

That is above its ten-year median of 16.8×, higher than on 87% of days in the last ten years.

Over that time it ranged from 10.5× in May 2019 to 32.8× in Sep 2024.

The median for 8 large drugmakers of a similar size is 23.4×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far24.6×20.9×26.7×
202523.8×21.8×30.4×
202426.9×20.3×32.8×
202320.1×14.9×20.1×
202216.4×15.1×18.2×
202117.1×15.6×18.9×
202017.0×13.6×18.6×
201915.2×10.5×15.3×
201812.1×11.3×13.6×
201711.8×11.0×13.3×
201611.4×10.6×14.5×
201514.9×13.8×20.0×
201420.5×15.8×21.3×
201315.9×10.0×16.3×
201210.3×10.3×13.6×
201112.5×7.6×12.5×
201010.5×7.7×10.9×

Against its peers

Companies in Drug Manufacturers - General nearest Amgen's size, closest first, today.

CompanyEV/EBIT
AMGNAmgen24.6×
GILDGilead Sciences23.4×
PFEPfizer14.5×
MRKMerck20.4×
BMYBristol-Myers Squibb12.4×
ABBVAbbVie27.2×
JNJJohnson & Johnsonn/m
LLYEli Lilly and35.7×
BIIBBiogen26.3×
Peer median23.4×

Where Amgen ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Amgen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.